PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation
about
JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indicationsAcute erythroleukemia: diagnosis and managementt(5;12)(q23-31;p13) with ETV6-ACSL6 gene fusion in polycythemia veraJAK and MPL mutations in myeloid malignancies.Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies.A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition.BCR-JAK2 drives a myeloproliferative neoplasm in transplanted mice.FOP is a centriolar satellite protein involved in ciliogenesis.Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies.JAK2 tyrosine kinase phosphorylates and is negatively regulated by centrosomal protein Ninein.Enu mutagenesis identifies a novel platelet phenotype in a loss-of-function Jak2 allele.Expression of TEL-JAK2 in primary human hematopoietic cells drives erythropoietin-independent erythropoiesis and induces myelofibrosis in vivoBigelovin inhibits STAT3 signaling by inactivating JAK2 and induces apoptosis in human cancer cells.The centriolar satellite proteins Cep72 and Cep290 interact and are required for recruitment of BBS proteins to the cilium.Chronic myeloproliferative disorders: a tyrosine kinase tale.Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disordersThe role of Janus kinases in haemopoiesis and haematological malignancy.Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinasesPCM1-JAK2-fusion: a potential treatment target in myelodysplastic-myeloproliferative and other hemato-lymphoid neoplasms.A structure-function perspective of Jak2 mutations and implications for alternate drug design strategies: the road not taken.JAKs go nuclear: emerging role of nuclear JAK1 and JAK2 in gene expression and cell growth.JAK2 inhibition for the treatment of hematologic and solid malignancies.Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application.Should myeloid and lymphoid neoplasms with PCM1-JAK2 and other rearrangements of JAK2 be recognized as specific entities?Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?Mutations in tyrosine kinase and tyrosine phosphatase and their relevance to the target therapy in hematologic malignancies.Centrosomal targeting of tyrosine kinase activity does not enhance oncogenicity in chronic myeloproliferative disorders.The role of the Janus-faced transcription factor PAX5-JAK2 in acute lymphoblastic leukemia.Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas.Implication of MAPK1/MAPK3 signalling pathway in t(8;9)(p22;24)/PCM1-JAK2 myelodysplastic/myeloproliferative neoplasms.Hematologic malignancies with PCM1-JAK2 gene fusion share characteristics with myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB, and FGFR1.
P2860
Q26782539-181E912B-E78E-41B9-BCCC-812D250C7EFDQ28298763-B28E2B25-50A3-494C-8071-A4B6951F69F7Q28304448-963091D7-5634-415F-BDF8-06CEC974E843Q33378737-C70124B9-98D1-4A2C-AF2A-1863B3374498Q33586552-CB23327A-9782-4300-B159-3FF3A8FFAAE5Q34065882-74F7A9C6-F17E-4891-A3B1-BD92B84B355CQ34461890-660FA20A-1424-4842-BF4B-9FEC0B962E97Q34648100-9CA49BEA-BF12-45A6-8720-5CF632CEEEE1Q34718163-901798D7-0677-48EA-9AF0-F6CD05B0E4D3Q34968444-746B7FB6-D941-47D4-A7F3-32737C9FFE88Q35005652-1B96BF30-8995-4772-B52F-83DC4D2E1EA2Q35120026-04DFE460-E6C3-4264-B09A-11B3493088C6Q35289346-4EA2DCAC-1194-4483-BE9F-290898375F4EQ36202725-7AB7363C-EABD-4446-B0AE-F7038FE3A188Q36337918-081EB931-F5A4-4F17-86EF-6902B1D42643Q36374813-3296B894-53BC-496C-AF88-D3AA5160E65BQ36527760-650720F8-0B62-4B5D-9EDB-DCC3C778977EQ37379320-35DB927D-D6D1-4D50-9AE8-24461DAF70B8Q37687519-037FCF8E-2AF9-491A-9895-5555F2821045Q37810947-8068DFD1-23C7-4C3F-B234-DA078DDE0F36Q37921836-89D73117-A0AF-4B5A-B97B-803C3252834DQ37926574-230367C7-6060-4E4E-8ED1-9B1E89F628E6Q38001733-FE6DA0B2-B0F9-46D5-A73B-8DDB7B782A59Q38164139-3B6EE9AF-460A-418B-820F-5A629D36D3D7Q38218909-2791B76E-49FD-4EE0-8F24-BB4518DCBB57Q38292400-9C01615C-7625-41D9-89B2-A551CB28BEE2Q38357132-155B0FD8-F6DD-430F-AC61-3039DFFAEF09Q39455159-4B0709B2-2D37-4ADC-8D93-970F9615C85BQ41681563-C2C6AF46-23C0-4E7C-B874-200FEBF2824AQ44855240-5DDEE5C9-B78F-49C2-A9F1-0FB239493000Q50967796-A9D31D3F-ABDC-44DE-AA8C-6BEC193E821FQ54450582-4229AB0D-C7D0-4151-936E-DFA40DCEE035
P2860
PCM1-JAK2 fusion in myeloproliferative disorders and acute erythroid leukemia with t(8;9) translocation
description
2005 nî lūn-bûn
@nan
2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
PCM1-JAK2 fusion in myeloproli ...... emia with t(8;9) translocation
@ast
PCM1-JAK2 fusion in myeloproli ...... emia with t(8;9) translocation
@en
PCM1-JAK2 fusion in myeloproli ...... emia with t(8;9) translocation
@nl
type
label
PCM1-JAK2 fusion in myeloproli ...... emia with t(8;9) translocation
@ast
PCM1-JAK2 fusion in myeloproli ...... emia with t(8;9) translocation
@en
PCM1-JAK2 fusion in myeloproli ...... emia with t(8;9) translocation
@nl
prefLabel
PCM1-JAK2 fusion in myeloproli ...... emia with t(8;9) translocation
@ast
PCM1-JAK2 fusion in myeloproli ...... emia with t(8;9) translocation
@en
PCM1-JAK2 fusion in myeloproli ...... emia with t(8;9) translocation
@nl
P2093
P2860
P356
P1433
P1476
PCM1-JAK2 fusion in myeloproli ...... emia with t(8;9) translocation
@en
P2093
Adélaïde J
Chaffanet M
Gelsi-Boyer V
Giraudier S
Letessier A
P2860
P2888
P304
P356
10.1038/SJ.LEU.2403879
P407
P577
2005-09-01T00:00:00Z
P5875
P6179
1024086936